Bilateral Interstitial Pneumonia Diagnosis and Treatment

Introduction to Interstitial Pneumonia

The American Thoracic Society recommends a multidisciplinary diagnostic approach to identify the specific cause of bilateral interstitial pneumonia, with treatment tailored to the underlying etiology, focusing on immunosuppressive therapy for inflammatory patterns and antifibrotic agents for fibrotic patterns 1, 2

Idiopathic pulmonary fibrosis (IPF) is characterized by the histologic pattern of usual interstitial pneumonia (UIP) with bibasilar reticular abnormalities on HRCT, according to the American Journal of Respiratory and Critical Care Medicine 1, 2
Nonspecific interstitial pneumonia (NSIP) shows bilateral symmetric ground glass opacities or bilateral air space consolidation on HRCT, as reported by the American Journal of Respiratory and Critical Care Medicine 2, 5
Acute interstitial pneumonia (AIP) is rapidly progressive hypoxemia with bilateral patchy ground-glass opacities and high mortality (>50%), according to the American Journal of Respiratory and Critical Care Medicine 4
Connective tissue disease-related ILD (CTD-ILD) includes systemic sclerosis, rheumatoid arthritis, and inflammatory myopathies, as stated by Autoimmunity Reviews 6

High-resolution CT (HRCT) patterns, such as UIP and NSIP, are essential for diagnosis, with the American Journal of Respiratory and Critical Care Medicine recommending HRCT for patients with suspected interstitial pneumonia 1, 2, 5
Laboratory and clinical assessment, including pulmonary function tests and serological testing, are crucial for excluding known causes of interstitial lung disease, as recommended by the American Journal of Respiratory and Critical Care Medicine 1, 8
Surgical lung biopsy is recommended in patients with suspected interstitial pneumonia who have atypical clinical or radiological features, according to the American Journal of Respiratory and Critical Care Medicine 1, 8

For idiopathic pulmonary fibrosis (IPF), the American Journal of Respiratory and Critical Care Medicine suggests considering antifibrotic agents (nintedanib, pirfenidone) for progressive disease, and lung transplantation for eligible patients 1, 6, 8
For connective tissue disease-related ILD, Autoimmunity Reviews recommends regular monitoring with PFTs every 3-6 months and HRCT as needed to assess progression, and considering nintedanib for RA-ILD 6
For acute interstitial pneumonia, the American Journal of Respiratory and Critical Care Medicine suggests supportive care similar to ARDS management, and considering high-dose corticosteroids, though efficacy is unproven 4

Autoimmunity Reviews recommends short-term PFTs (within 3 months) and HRCT (within 6 months) after diagnosis to determine rate of progression, and more frequent PFTs (every 3-6 months) for moderate-to-severe disease or progressive disease 6
The American Journal of Respiratory and Critical Care Medicine suggests HRCT should be repeated within the first 3 years to identify progressive disease 6